Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...

People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough of ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Ozempic is generally more effective in lowering blood sugar and ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

News 8 On Your Side is investigating a critical drug shortage frustrating diabetics who need the medicine.Investigator Susan Shapiro looked into the shortage and what the drug maker had to say about ...

Eli Lilly and Company (LLY) announced that the FDA granted approval to two higher doses, 3 mg and 4.5 mg, of its GLP-1 receptor agonist, Trulicity. The approval was based on data from the AWARD-11 ...

Eli Lilly’s diabetes drugs Mounjaro and Trulicity are in short supply due to heightened demand for the medication, the Food and Drug Administration (FDA) announced recently. Pharmacies are ...

KNOXVILLE, Tenn. (WATE) — It’s hard to watch TV these days without seeing an article or ad praising weight-loss wonder drugs. Some of these drugs, like Trulicity, are approved to treat type 2 diabetes ...

Gavreto approved for metastatic lung cancer with RET gene fusions Blueprint Medicines’ Gavreto (pralsetinib capsules) has been granted accelerated approval for treating adults with metastatic ...